Trial Profile
A pivotal trial of Ruxolitinib for Essential thrombocythemia
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 11 May 2017
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia
- Focus Registrational; Therapeutic Use
- Sponsors Incyte Corporation
- 11 May 2017 New trial record
- 04 May 2017 According to an Incyte Corporation media release, this program is expected begin in 2017.